Developments in China’s biotechnology sector, from research breakthroughs and diagnostics to industrial biotech and manufacturing.
For global pharmaceutical and tech investors, the convergence of deep-pocketed AI giants and drug discovery marks a pivotal shift in how new therapies may be developed. In a move that…
A more cautious regulatory stance on offshore corporate structures signals a strategic shift, prioritizing oversight over unfettered access to foreign capital and setting a new calculus for growth-stage companies in…
As the global race for a Covid-19 cure accelerates, China’s biotechnology sector is experiencing a powerful wave of consolidation and capital inflows, signalling a strategic shift in the country’s pharmaceutical…
The regulatory shift signals a maturing, more cautious approach to capital markets, prioritizing oversight over unbridled growth in sensitive sectors. A significant shift is underway in how China regulates its…
For global biotech and life sciences firms weighing an IPO in Asia, Hong Kong’s willingness to rewrite its listing rules signals a serious effort to draw capital and talent away…
No products in the cart.
